S095029
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | S095029 |
| Trade Name | |
| Synonyms | S-095029|S 095029|Sym 025|Sym-025|Sym025 |
| Drug Descriptions |
S095029 is a monoclonal antibody that targets natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), which may result in an antitumor immune response mediated by NK cells and cytotoxic T-lymphocytes (NCI Drug Dictionary). |
| DrugClasses | NKG2A Antibody 4 |
| CAS Registry Number | NA |
| NCIT ID | C185890 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cemiplimab + S095029 | Cemiplimab S095029 | 0 | 1 |
| Futuximab + S095029 + Sym021 | Futuximab S095029 Sym021 | 0 | 1 |
| Modotuximab + S095029 + Sym021 | Modotuximab S095029 Sym021 | 0 | 1 |
| Pembrolizumab + S095029 | Pembrolizumab S095029 | 0 | 1 |
| S095029 | S095029 | 0 | 1 |
| S095029 + Sym021 | S095029 Sym021 | 0 | 1 |
CKB BOOST